Literature DB >> 2350572

Study duration for clinical trials with survival response and early stopping rule.

K Kim1, A A Tsiatis.   

Abstract

A comparative clinical trial with built-in sequential stopping rules allows earlier-than-scheduled stopping, should there be a significant indication of treatment difference. In a clinical trial where the major outcome is time (survival time or response) to a certain event such as failure, the design of the study should determine how long one needs to accrue patients and follow through until there is a sufficient number of events observed during the entire study duration. This paper proposes a unified design procedure for group sequential clinical trials with survival response. The time to event is assumed to be exponentially distributed, but the arguments extend naturally to the proportional hazards model after suitable transformation on the time scale. An example from the Eastern Cooperative Oncology Group (ECOG) is given to illustrate how this procedure can be implemented. The same example is used to explore the overall operating characteristics and the robustness of the proposed group sequential design.

Entities:  

Mesh:

Year:  1990        PMID: 2350572

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  11 in total

1.  Duration of accrual and follow-up for two-stage clinical trials.

Authors:  L D Case; T M Morgan
Journal:  Lifetime Data Anal       Date:  2001-03       Impact factor: 1.588

2.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors:  L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

3.  Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214.

Authors:  Elizabeth M Gore; Kyounghwa Bae; Stuart J Wong; Alexander Sun; James A Bonner; Steven E Schild; Laurie E Gaspar; Jeffery A Bogart; Maria Werner-Wasik; Hak Choy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

Review 4.  Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.

Authors:  Daniel A Hamstra; Kyounghwa Bae; Miljenko V Pilepich; Gerald E Hanks; David J Grignon; David G McGowan; Mack Roach; Colleen Lawton; R Jeffrey Lee; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-31       Impact factor: 7.038

5.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

Authors:  Beryl McCormick; Kathryn Winter; Clifford Hudis; Henry Mark Kuerer; Eileen Rakovitch; Barbara L Smith; Nour Sneige; Jennifer Moughan; Amit Shah; Isabelle Germain; Alan C Hartford; Afshin Rashtian; Eleanor M Walker; Albert Yuen; Eric A Strom; Jeannette L Wilcox; Laura A Vallow; William Small; Anthony T Pu; Kevin Kerlin; Julia White
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors:  Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 7.  Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.

Authors:  Mark R Green; Stephen L George; Richard L Schilsky
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

8.  Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.

Authors:  Luis Souhami; Kyounghwa Bae; Miljenko Pilepich; Howard Sandler
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

9.  Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.

Authors:  Alexander Sun; Chen Hu; Stuart J Wong; Elizabeth Gore; Gregory Videtic; Swati Dutta; Mohan Suntharalingam; Yuhchyau Chen; Laurie E Gaspar; Hak Choy
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

10.  Information fraction estimation based on the number of events within the standard treatment regimen.

Authors:  Ha M Dang; Todd Alonzo; Meredith Franklin; Wendy J Mack; Mark D Krailo; Sandrah P Eckel
Journal:  Biom J       Date:  2020-07-06       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.